Allena Stock Financials

ALNA
 Stock
  

USD 0.026  0.0007  2.77%   

We suggest to use Allena Pharmaceuticals fundamental analysis to find out if markets are presently mispricing the company. Put another way you can use it to find out if Allena Pharmaceuticals is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate thirty available fundamental indicators for Allena Pharmaceuticals, which can be compared to its rivals. To ensure the equity is not overpriced, please confirm all Allena Pharmaceuticals financials, including its total debt, earnings per share, and the relationship between the net income and book value per share . As Allena Pharmaceuticals appears to be a penny stock we also recommend to validate its price to earning numbers. Use Allena Pharmaceuticals to enhance the returns of your portfolios. Benchmarks are essential to demonstrate the utility of optimization algorithms. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Allena Pharmaceuticals to be traded at $0.0312 in 90 days.
  
With this module, you can analyze Allena financials for your investing period. You should be able to track the changes in Allena Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past Allena Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Allena Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Allena Pharmaceuticals' assets may result in an increase in income on the income statement.
Chance Of Financial Distress
Over 67
Allena Pharmaceuticals has more than 67 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Allena Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Allena Pharmaceuticals' official financial statements usually reflect Allena Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Allena Pharmaceuticals. For example, before you start analyzing numbers published by Allena accountants, it's critical to develop an understanding of what Allena Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Allena Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allena Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Allena Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Allena Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Allena Pharmaceuticals' management to manipulate its earnings.

Allena Pharmaceuticals Company Summary

Allena Pharmaceuticals competes with Kadokawa Corp, Educational Dev, RELX PLC, New York, and Pearson Plc. Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 17 people.
InstrumentUSA Stock View All
ExchangeNMS Exchange
Business Address142 F North
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.allenapharma.com
Phone617 467 4577
CurrencyUSD - US Dollar
You should never invest in Allena Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Allena Stock, because this is throwing your money away. Analyzing the key information contained in Allena Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Allena Pharmaceuticals Key Financial Ratios

Generally speaking, Allena Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Allena Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Allena Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Allena Pharmaceuticals reports annually and quarterly.

Allena Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Allena Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Allena Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allena Pharmaceuticals competition to find correlations between indicators driving Allena Pharmaceuticals's intrinsic value. More Info.
Allena Pharmaceuticals is number one stock in total asset category among related companies. It is number one stock in return on equity category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Allena Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Allena Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allena Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Allena Pharmaceuticals Market Fundamentals

 Quote0.026
 Change(%) 2.77 
 Change0.0007 
 Open0.0253
 Low0.0252
 High0.028
 Volume1039337.000
 ExchangeNMS

About Allena Pharmaceuticals Financials

What exactly are Allena Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Allena Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Allena Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Allena Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Allena Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Allena Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Allena Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Allena has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Allena Pharmaceuticals October 3, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Allena Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Allena Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Allena Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Allena Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Allena Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.05)
Maximum Drawdown143.67
Value At Risk(24.21)
Potential Upside10.53
Please continue to Trending Equities. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Tools for Allena Stock

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go